Funder DirectoryFOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS
Back to directory

Grantmaking public charityEIN 980407553

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

GRANDSACONNEX

Total Assets

$51.3M

FY 2024

Annual Giving

$1.4M

FY 2024

Grants Made

10

FY 2024

Avg Grant

$141K

FY 2024

Grant Range

Typical

Deadlines

Applications

Programs & Activities

Program 1

$5.2M

See schedule O

Program 2

$4.9M

See schedule O

Program 3

$22.1M

Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa

Focus Areas

Medical Research

Financial Snapshot

2024 filing

Total Revenue

$49.3M

Total Expenses

$56.8M

Giving Over Time

4 years

Giving over time from 2020 to 2024. Peak $18.4M in 2022. Hover bars for details.

Total dollars recorded per filing year. Scale adjusts to the foundation's range.

Top Recipients

91 grants

Biomeme
$4.7M
2 grants
Diagnostic Consulting Network Inc
$3.6M
2 grants
Transnational TechnologiesInc
$3.2M
1 grant
WHO-PAHO
$2.3M
1 grant
Elizabeth Glaser Pediatric Aids Foundation
$1.0M
2 grants

Grant Size Distribution

91 grants

<$10K
8
grants
$10–50K
29
grants
$50–250K
26
grants
$250K–1M
22
grants
$1–5M
6
grants
$5M+

Geographic Focus

18 states

Massachusetts
$6.7M
22% of total
California
$6.4M
21% of total
Pennsylvania
$4.7M
15% of total
District of Columbia
$3.8M
12% of total
Florida
$3.2M
11% of total
North Carolina
$1.7M
6% of total
New York
$1.2M
4% of total
Washington
$824K
3% of total
Texas
$549K
2% of total
Maryland
$367K
1% of total

+8 more states

Ready to work on a proposal for FOUNDATION FOR INNOVATIVE NEW DIAGNOSTI…?

Open a draft with this funder pre-selected. Add guidelines when you have them.

Draft an application for FOUNDATION FOR INNOVATIVE NEW DIAGNOSTI…
Funder alerts

Track FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

Get an email when Grantivo has new data for FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS, such as a fresh IRS filing, updated financials, or newly reported grants. No account needed.

Free. Unsubscribe anytime. Or create an account to draft an application.

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS — Grants, Financials & Contact | Grantivo